- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Clear Cell Renal Cancer, Bone Metastases of a Malignant Tumor, Clear Cell Renal Cell Carcinoma, Bone, Metastatic Cancer, Metastatic Cancer, Metastatic Renal Cell Carcinoma, Metastases to Bone
- Interventions
- Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT), Bone Scan, Computerized tomography (CT) Scan
- Drug · Radiation · Procedure
- Lead sponsor
- Kelly Fitzgerald, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–39
of 15
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Uterine Cancer, Endometrial Cancer
- Interventions
- Zanzalintinib, Paclitaxel
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 4
- States / cities
- San Francisco, California • St Louis, Missouri • Albuquerque, New Mexico + 1 more
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer
- Interventions
- Cabozantinib, Zanzalintinib, Atezolizumab, Nivolumab, Abiraterone, Prednisone, Enzalutamide
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Bay Shore, New York • Kettering, Ohio
- Conditions
- Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma, Bone Sarcoma, Translocation-associated Soft Tissue Sarcoma, Synovial Sarcomas, Osteosarcoma Metastatic, Ewing Sarcoma, Ewing Sarcoma Metastatic, Sarcoma Metastatic, Sarcoma of Bone
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography, Multigated Acquisition Scan, Zanzalintinib
- Procedure · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Renal Cell Carcinoma
- Interventions
- Belzutifan, Zanzalintinib, Cabozantinib
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 904 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 10
- States / cities
- Anchorage, Alaska • Fullerton, California • Los Angeles, California + 6 more
- Conditions
- Phase 2, Zanzalintinib, Pembrolizumab, Advanced/Metastatic, Soft-Tissue Sarcoma
- Interventions
- Zanzalintinib, Pembrolizumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 15
- States / cities
- Fullerton, California • Orange City, Florida • Tampa, Florida + 12 more
- Conditions
- High Grade Neuroendocrine Neoplasms
- Interventions
- Zanzalintinib
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • St Louis, Missouri
- Conditions
- Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
- Interventions
- Angiogram, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Single Photon Emission Computed Tomography, Tremelimumab, Yttrium-90 Microsphere Radioembolization, Zanzalintinib
- Procedure · Biological · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Meningioma
- Interventions
- Zanzalintinib
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Santa Monica, California + 14 more
- Conditions
- Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local, Neoplasm Metastasis, Recurrent Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma
- Interventions
- Zanzalintinib, Cetuximab, Pembrolizumab
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma, Locally Advanced Thyroid Gland Follicular Carcinoma, Locally Advanced Thyroid Gland Oncocytic Carcinoma, Locally Advanced Thyroid Gland Papillary Carcinoma, Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic Poorly Differentiated Thyroid Gland Carcinoma, Metastatic Thyroid Gland Follicular Carcinoma, Metastatic Thyroid Gland Oncocytic Carcinoma, Metastatic Thyroid Gland Papillary Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Refractory Poorly Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland Oncocytic Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Thyroid Gland Follicular Carcinoma AJCC v8, Stage III Thyroid Gland Papillary Carcinoma AJCC v8, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IV Thyroid Gland Follicular Carcinoma AJCC v8, Stage IV Thyroid Gland Papillary Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Survey Administration, X-Ray Imaging, Zanzalintinib
- Procedure · Other · Drug
- Lead sponsor
- Jochen Lorch
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Torrance, California • Chicago, Illinois
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
- Interventions
- Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more
- Conditions
- Aggressive Variant Prostate Carcinoma
- Interventions
- Zanzalintinib
- Drug
- Lead sponsor
- Deepak Kilari
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Atezolizumab, Cobimetinib, RO6958688, Docetaxel, CPI-444, Pemetrexed, Carboplatin, Gemcitabine, Linagliptin, Tocilizumab, Ipatasertib, Bevacizumab, Sacituzumab Govitecan, Radiation, Evolocumab, Tiragolumab, XL092, Camonsertib
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 4
- States / cities
- Las Vegas, Nevada • New York, New York • Cleveland, Ohio + 1 more